Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Natalizumab 300 mg in Relapsing Multiple Sclerosis
2014-000917-30Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Persistent anti-natalizumab antibodies. Started Jul 2014; status: terminated.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-000917-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000917-30.